Trehalose is under clinical development by Seelos Therapeutics and currently in Phase III for Oculopharyngeal Muscular Dystrophy. According to GlobalData, Phase III drugs for Oculopharyngeal Muscular Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Trehalose LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Trehalose overview

Trehalose is under development for the treatment of oculopharyngeal muscular dystrophy (a type of congenital myopathy), Huntington’s disease (HD), friedreich ataxia, Sanfilippo syndrome and undisclosed liver disease. The drug candidate is administered through intravenous infusion. Trehalose is a naturally occurring sugar containing two D-glucose units in an alpha,alpha-1,1 linkage. Trehalose reduces the polyA binding protein nuclear 1 (PABPN1) aggregates seen in oculopharyngeal muscular dystrophy.

It was also under development for the treatment of spino bulbar cerebellar ataxia (SBMA)/Kennedy’s disease, Alzheimer's disease, Amyotrophic lateral sclerosis and Machado-Joseph disease/spinocerebellar ataxia 3 (SCA3).

Seelos Therapeutics overview

Seelos Therapeutics (Seelos) is a clinical-stage biopharmaceutical company that focuses on developing novel technologies and therapeutics for the treatment of central nervous system (CNS) and other rare disorders. Its lead programs include SLS-002, SLS-005, and pipeline products include SLS-004, SLS-007, SLS-008, SLS-010 and SLS-012. Seelos pipeline products find application in treating various multiple CNS disorders including parkinson’s disease, sanflippo syndrome, suicidality post-traumatic stress disorders, major depressive disorders and other diseases such as atopic dermatitis, asthma, and pediatric esophagitis. It operates along with its subsidiaries. Seelos is headquartered in New York, the US.

For a complete picture of Trehalose’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.